ELSA
Dead / Abandoned — Abandoned — no statement of use filed (as of 30 Mar 2026)
What this means for you
This application is over — abandoned 30 Mar 2026. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98507838
- Mark type
- Stylized text
- Filed
- 18 Apr 2024
- Published for opposition
- 01 Jul 2025
- Abandoned
- 30 Mar 2026
- Attorney of record
- Perry Gattegno
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of central nervous system diseases, neuromuscular diseases, metabolic diseases, and diseases related to RNA processing and translation
- Class 042 — Scientific and technological services: Biochemical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Biotechnology research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Gene therapy research, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Pharmaceutical drug development services, namely, development and design of anti-sense oligonucleotides; Pharmaceutical products development, namely, development and design of anti-sense oligonucleotides; Pharmaceutical research and development, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of RNA-targeted drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of nucleic acids, biologics, central nervous system diseases, metabolic diseases, and small molecule drugs, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research and development in the field of gene therapy, namely, using bioinformatics to develop knowledge of the RNA transcript splicing regulation machinery to improve efficacy; Research and development in the pharmaceutical and biotechnology fields, namely, development of bioinformatics techniques for the purpose of designing anti-sense oligonucleotides; Research, development, engineering and testing services in the fields of immunopharmaceuticals and vaccines, namely, development and design of anti-sense oligonucleotides; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy, namely, development and design of anti-sense oligonucleotides
Owner
- Fosun Pharma USA Inc., Princeton, NJ, US
- Fosun Pharma USA Inc., Princeton, NJ, US
Prosecution history
- 30 Mar 2026 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 30 Mar 2026 — ABANDONMENT - NO USE STATEMENT FILED
- 26 Aug 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Jul 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Jul 2025 — PUBLISHED FOR OPPOSITION
- 25 Jun 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 30 May 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 May 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 May 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 May 2025 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 09 May 2025 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 09 May 2025 — FINAL REFUSAL E-MAILED
- 09 May 2025 — FINAL REFUSAL WRITTEN
- 18 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 18 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE